PONVORY

Peak

ponesimod

Vanda Pharmaceuticals
NDAORALTABLET
Approved
Mar 2021
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
3

Mechanism of Action

Sphingosine 1-Phosphate Receptor Modulators

Pharmacologic Class:

Sphingosine 1-phosphate Receptor Modulator

Clinical Trials (3)

NCT07362017Phase 3Not Yet Recruiting

Open Label Study to Investigate the Safety and Efficacy of Ponesimod in Moderate-to-Severe Chronic Plaque Psoriasis

Started Jan 2026
300 enrolled
Moderate-to-severe Chronic Plaque Psoriasis
NCT05552196Phase 1Completed

A Study of Ponesimod in Healthy Adult Participants

Started Oct 2022
28 enrolled
Healthy
NCT03882255Phase 1Completed

A Study of Ponesimod in Healthy Adult Participants Receiving Propranolol at Steady State

Started Mar 2019
52 enrolled
Healthy

Loss of Exclusivity

LOE Date
Oct 10, 2042
202 months away
Patent Expiry
Oct 10, 2042
Exclusivity Expiry
Mar 18, 2026

Patent Records (5)

Patent #ExpiryTypeUse Code
RE43728
Nov 16, 2029
SubstanceProduct
—
9062014
May 6, 2032
SubstanceProduct
U-2774
10220023
Dec 10, 2035
U-3103
12336980
Dec 10, 2035
U-3103
11951097
Oct 10, 2042
U-3891
Company
VP
Vanda Pharmaceuticals
WASHINGTON, DC
External Resources
DailyMed
Full prescribing information
FDA Drugs@FDA
FDA approval history
RxNorm
Drug nomenclature & identifiers